Davon Gray is the Vice President of Policy for Purpose Built Communities®. Gray has more than 25 years of experience in advocacy, political affairs and policy strategy. He previously worked for the American Institute of Architects in various capacities, including Managing Director of Advocacy and Engagement programs. Gray is a 12-year veteran of the United States Army National Guard and Reserves. He graduated from the University of Southern Mississippi with a bachelor's degree in political science, and he received his master's degree in public administration from DeVry University.

Michael Olivieri serves as the Senior Vice President at Associated Development Management Corp. His entrepreneurial career spans nearly 30 years, where he has remained active in real estate development and civic endeavors, including mentoring young people. Michael holds a bachelor's degree in finance from George Mason University.

The Virginia Housing Board of Commissioners is responsible for guiding Virginia Housing by adopting policies, approving budgets and overseeing organizational operations. Board members are appointed by the governor and include the state treasurer and the director of the Virginia Department of Housing and Community Development. For more information about Virginia Housing's leadership team, visit VirginiaHousing.com.

About Virginia Housing

By investing in the power of home, Virginia Housing transforms where and how thousands of Virginians live and thrive, strengthening communities and the economy. Virginia Housing has worked for over 50 years in partnership with the public and private sectors to help Virginians attain quality, affordable housing. While receiving no state taxpayer dollars, Virginia Housing raises money in capital markets to provide mortgages to first-time homebuyers, financing for rental developments and neighborhood revitalization efforts. Virginia Housing invests in innovations in affordable housing and makes homes for people with disabilities and older Virginians more livable. Learn more at VirginiaHousing.com and review the most recent annual report.

SOURCE Virginia Housing

Share this article

HSINCHU, Sept. 21, 2026 /PRNewswire/ -- ICP DAS will showcase its latest intelligent transportation technologies at APTA 2026 TRANSform & EXPO, taking place October 4–7 at McCormick Place in Chicago, Illinois. Visitors are invited to Booth 4625 to experience a live demonstration of the iTLC-9000 Series Redundant Multifunctional Traffic Signal Control System, designed to improve traffic safety, operational reliability, and smart intersection management.

The booth will feature a simulated intersection where the iTLC-9000 controls two sets of actual traffic signals, demonstrating real-time traffic signal operation. Built with a fully modular and redundant architecture, the iTLC-9000 ensures continuous operation, simplifies maintenance with hot-swappable modules, and supports up to 16 traffic signal phases and 32-way complex intersection. The system also features rapid primary/backup controller switchover, real-time abnormal status notifications, proactive maintenance functions, cybersecurity protection for networked traffic infrastructure, and an intuitive color touchscreen for efficient operation.

ICP DAS will also demonstrate an AI-powered intelligent traffic solution utilizing NVIDIA GPU technology. By analyzing live traffic video, the system can identify traffic flow conditions, detect approaching emergency vehicles, and detect traffic violations and recognize the associated license plates, enabling the iTLC-9000 to optimize signal timing, improve traffic efficiency, and support faster operational response for modern smart city applications.

In addition to the iTLC-9000 Series, ICP DAS will showcase complementary intelligent transportation solutions, including the WISE-5231 Edge Computing Controller, PET-7016M Ethernet Remote I/O Module, MDC-714 Modbus Data Concentrator, DL-1038-WF Environmental Monitoring Module, ALM-Horn-WF-BR Piezoelectric Alarm Horn, and iTLC-LC-NOD-01 and iTLC-LC-NOD-02 Light Control Unit Modules, providing a complete ecosystem for intelligent traffic control, monitoring, communication, and edge computing applications.

Visit ICP DAS at Booth 4625 to discover how AI, edge computing, and redundant traffic control technologies are shaping the future of intelligent transportation systems.

About ICP DAS

Founded in 1993 and headquartered in Taiwan, ICP DAS is a global leader in industrial automation and IoT solutions. With more than three decades of expertise, the company delivers hardware and software that empower businesses to embrace Industry 4.0 and the Industrial Internet of Things (IIoT). By combining strong R&D capabilities with international market experience, ICP DAS continues to drive innovation that transforms factories, utilities, and infrastructure worldwide.

For more information, please visit: https://www.icpdas.com

SOURCE ICP DAS Co., Ltd.

Share this article

MARTIN, Mich., Sept. 21, 2026 /PRNewswire/ -- On a day when Top Fuel points leader Shawn Langdon again made the fastest run in Top Fuel history, the standout powered to the win on Monday at the Dodge NHRA Great Lakes Nationals presented by MOPAR, defeating Spencer Massey in the final round at U.S. 131 Motorsports Park to finish off one of the most dominant days in NHRA history.

Jordan Vandergriff (Funny Car), Troy Coughlin Jr. (Pro Stock) and John Hall (Pro Stock Motorcycle) also won the 15th of 20 races during the 2026 NHRA Mission Foods Drag Racing Series season and the first of six races in the Countdown to the Championship playoffs.

In the final round, Langdon went 3.664-seconds at 346.15 mph in his 12,000-horsepower Kalitta Air dragster, powering past Massey's 3.764 at 327.75 to pick up his sixth victory of the season and second in a row.

He moved back into the points lead, delivering one unbelievable statement run after another. That included an incredible blast of 3.663 at 346.95 in the semifinals against teammate Doug Kalitta, making the fastest pass in NHRA history.

That shattered the run of 345.00 from Valdosta that Langdon ran in May and Langdon again topped 346 mph in the finals against Massey. All four of his runs on Monday were 342 mph or faster, while he also made the quickest run of the year, going 3.652 to open the day against Maddi Gordon.

"It just goes to show it takes everything," Langdon said. "You have a track like U.S. 131 that takes a lot of pride in their facility. It's a great track and then you get some good conditions and really anything's possible. It all starts there and my guys have been doing such a great job.

"Brian (Husen, crew chief) made perfect calls and he races smart. It was just getting everything in sync and the car showed what it was capable of. We knew that it was going to be good, but to be able to do that for four runs today, I'm just proud of my guys to get this win. There was just a lot of good things going on this weekend."

Vandergriff, who qualified last in 16th, moved to second in points with his third victory of the season for John Force Racing, going 3.858 at 329.43 in his Chevrolet to defeat points leader Matt Hagan in the finals of the Dodge NHRA Great Lakes Nationals presented by MOPAR.

Coughlin won for the first time in 41 races, slipping past points leader Matt Hartford with a 6.515 at 209.69 in his Chevrolet Camaro. It is his sixth career win and first since 2024.

Hall earned his first win of the season after a run of 6.808 at 194.22 on his Buell in the championship round against first-time finalist Marc Ingwersen.

The NHRA Mission Foods Drag Racing Series returns to action Friday through Sunday with the inaugural NHRA Nationals at The Rock at Rockingham Dragway in Rockingham, N.C.

-NHRA-

SOURCE National Hot Rod Association (NHRA)

Share this article

Inglewood Associates and Gordon Brothers Provide Update on Sale Process for 925 Euclid Avenue in Cleveland

CLEVELAND, Sept. 21, 2026 /PRNewswire/ -- Inglewood Associates and Gordon Brothers today announced an update regarding the court-supervised sale process for the property located at 925 Euclid Avenue, Cleveland, Ohio, commonly known as The 925 Building and The Centennial Building, and formerly known as the Huntington Building and the Union Commerce Building.

Following a comprehensive marketing effort and ongoing discussions with prospective purchasers, the Receiver has not selected a stalking horse bidder at this time. While Receiver and his advisors have had detailed discussions with numerous interested parties, the potential bidders have specifically indicated a preference to participating in a subsequent auction as opposed to submitting a Stalking Horse Bid.

The marketing process continues to generate substantial interest from both local, national and international investors, developers, unique users and other capital sources. Gordon Brothers and Inglewood Associates remain encouraged by the level of engagement and believe the property continues to attract significant attention from parties seeking a transformational redevelopment opportunity in downtown Cleveland.

The decision not to designate a stalking horse bidder does not alter the court-approved sale timeline authorized by the United States District Court for the Northern District of Ohio. Interested parties continue to conduct diligence and evaluate potential acquisition opportunities, and the Receiver remains focused on maximizing value through a transparent and competitive process. The sale procedures provide for the submission of qualified bids and, if appropriate, a competitive auction process designed to achieve the highest and best outcome for the property.

Qualified bids for the property are due on or before October 24, 2026. Prospective purchasers interested in participating in the process should continue to follow the applicable court-approved bidding procedures and deadlines.

While qualified bids remain due on or before October 24, 2026, the Receiver continues to evaluate all opportunities generated through the marketing process. Consistent with the court-approved sale procedures, the Receiver retains flexibility to pursue the transaction path that is determined to maximize value and achieve the highest and best outcome for stakeholders.

The 925 Building encompasses approximately 1.45 million square feet and occupies a prominent location at the intersection of East 9th Street and Euclid Avenue in Cleveland's central business district. The historic property is one of the city's most recognizable landmarks and represents a unique redevelopment opportunity.

About Inglewood Associates

Inglewood Associates LLC is a senior-led advisory firm helping owners, boards, and lenders create value and navigate critical turns since 1983. The firm's principals, who average 35 years each of financial, operational and ownership experience, have served in court driven processes as receivers, financial advisors and creditor trustees and served clients as interim and full-time CEO's, COO's, CRO's, and CFO's. To learn more about Inglewood.

About Gordon Brothers

Founded in 1903, Gordon Brothers delivers integrated solutions through our asset advisory services, lending and financing, and trading. With deep expertise in brands, industrial, retail and real estate, we are the original global asset expert, working across business growth stages to deliver liquidity, create security, enable growth and maximize asset value. We are headquartered in Boston with more than 30 offices across North America, Europe, the Middle East, Africa, and Asia Pacific.

The firm has been engaged by the Receiver as exclusive real estate consultant and advisory agent in connection with the sale of the property at 925 Euclid Avenue.

Media Contact:

John K Lane

[email protected]

Photo(s):

https://www.prlog.org/13172047

Press release distributed by PRLog

SOURCE Inglewood Associates LLC

Share this article

NEW YORK, Sept. 21, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, LLP was named one of "The Most Feared Law Firms in Litigation" in BTI Consulting Group's (BTI) Litigation Outlook 2027: More Aggressive. More Complexity. Higher Stakes. The recognition marks the firm's second consecutive year on BTI's list of law firms clients identify as those they least want to face across the table in litigation.

The firm also earned recognition across eight litigation categories: "Leader" for Class Action, Commercial Litigation, and Employment Litigation; "Distinguished" for Complex Commercial Litigation and Cybersecurity Litigation; and "Standout" for Complex Employment Litigation, Product Liability Litigation, and Intellectual Property (IP) Litigation.

BTI's report reflects feedback from legal decision-makers on the firms best suited to meet the most pressing needs in a litigation landscape defined by higher stakes, more complex claims, and increasingly aggressive disputes. The 2027 report underscores clients' heightened focus on firms with the strategic judgment, creativity, speed, and courtroom credibility needed to address novel and business-critical matters, including bet-the-company litigation, class actions, cybersecurity litigation, employment disputes, commercial litigation, intellectual property litigation, and product liability claims.

The 2027 rankings continue Greenberg Traurig's multiyear showing in BTI's litigation outlook series, including repeat recognition in Class Action, Commercial Litigation, Complex Commercial Litigation, Complex Employment Litigation, Employment Litigation, IP Litigation, and Product Liability Litigation.

About Greenberg Traurig: Greenberg Traurig, LLP has approximately 3,200 lawyers across 51 locations in the United States, Europe, the Middle East, Latin America, and Asia. The firm's broad geographic and practice range enables the delivery of innovative and strategic legal services across borders and industries. Recognized as a 2025 BTI "Best of the Best Recommended Law Firm" by general counsel for trust and relationship management, Greenberg Traurig is consistently ranked among the top firms on the Am Law Global 100, NLJ 500, and Law360 400. Greenberg Traurig is also known for its philanthropic giving, culture, innovation, and pro bono work. Web: www.gtlaw.com.

SOURCE Greenberg Traurig, LLP

Share this article

Olight's Best-Selling Clip Light Evolves: Oclip 2 Series Rotates and Tilts to Aim Where You Need It

HOUSTON, Sept. 21, 2026 /PRNewswire/ -- Olight launched the Oclip 2 Series during its O-Fan Day event, introducing the Oclip 2 Pro and Oclip 2 Ultra designed for mechanics, public safety professionals, outdoor enthusiasts and anyone who requires fully adjustable, hands-free lighting with multiple light sources. The Oclip 2 Series represents the next generation of Olight's best-selling clip-light line, a product line with more than one million users worldwide.

Both models feature an all-new dual-axis design that tilts the head up to 115° and rotates the clip a full 360°, allowing the beam to be freely aimed as needed after mounting without repositioning the mounting point. Self-locking pivots hold the selected angle in place. Durability testing covered 10,000 clipping cycles for the clip and 10,000 rotation cycles for the dual-axis mechanism.

The Oclip 2 Pro integrates three lighting modes in one compact body: pure flood, spot, and red light. Flood output reaches up to 530 lumens, spot range up to 125 meters, and red output up to 40 lumens.

Building on the Oclip 2 Pro's three-light configuration, the Oclip 2 Ultra adds UV light through an industry-first R/UV emitter that integrates red and UV light within its compact body, bringing the total to four light sources. Flood output reaches up to 580 lumens and spot range up to 130 meters, while UV output reaches up to 800 mW for inspections. Beyond lighting performance, the Oclip 2 Ultra adds an exclusive OAL aluminum body and head that combine high strength with scratch resistance, alongside the new OclipBeat breathing light, which changes color based on cumulative usage time.

Across the Oclip 2 Series, dual magnets at the MCC tail and clip allow the light to be secured to compatible metal surfaces in different orientations for hands-free illumination.

Both models support USB-C and MCC charging. Each Premium version includes a 1,000 mAh Mobile Charging Dock that automatically recharges the light on the go, extends total runtime to approximately twice that of the light alone, and displays the battery levels of both the light and dock.

The Oclip 2 Pro comes in Classic Black, High-Visibility Orange, and Tidal Blue, while the Oclip 2 Ultra comes in Olive Green, Onyx Black, and Amber Orange. Both models are available worldwide through the Olight Official Store, Amazon, and authorized retailers. Standard versions are priced at $49.99 for the Oclip 2 Pro and $69.99 for the Oclip 2 Ultra; pricing for other versions is available on the Olight Official Store.

About Olight

Founded in 2007, Olight is a global innovator in portable lighting, offering high-tech solutions for everyday carry, outdoor, tactical, and professional use. With over 1,200 patents and iF and Red Dot design recognitions, Olight serves users in over 100 countries.

Contact:

[email protected] 

SOURCE Olight Group Co., Ltd

Share this article

Merry Life Biomedical Advances Global Phase 2 Trial of TML-6, Exploring Cellular Protein Clearance in Early Alzheimer's Disease

Global study brings together nine Taiwan medical centers, seven Swedish sites, and four U.S. centers to evaluate an oral therapy focused on autolysosomal biology

TAIPEI, Sept. 21, 2026 /PRNewswire/ -- Merry Life Biomedical today announced the advancement of TML-6, a Taiwan-developed investigational oral therapy for early Alzheimer's disease, into a global Phase 2 study spanning Taiwan, Sweden, and the United States.

The study brings together 20 clinical sites, including nine medical centers in Taiwan, seven sites in Sweden, and four centers in the United States. It will evaluate TML-6 in approximately 210 participants with early Alzheimer's disease.

A New Approach to Alzheimer's Disease

Alzheimer's disease is characterized by the abnormal accumulation of proteins in and around brain cells, including amyloid plaques and tau tangles. Recently approved therapies have demonstrated that removing amyloid can slow clinical decline in people with early Alzheimer's disease. But even with treatment, the disease continues to progress.

TML-6 is being investigated through a new and potentially complementary approach. Research on TML-6 has increasingly focused on the autophagy–lysosomal pathway, which is responsible for clearing and recycling proteins and other cellular material. Preclinical studies have investigated its effects on autophagy lysosomal function in neurons and microglia, together with amyloid related pathology, oxidative stress, and inflammation.

"The next generation of Alzheimer's therapeutics must look beyond what accumulates in the brain and ask why neurons lose their ability to clear damaged proteins and maintain normal function," said Dr. Ih-Jen Su, Founder and Chairman of Merry Life Biomedical. "Research on TML-6 has increasingly pointed us toward the autophagy–lysosomal system, a fundamental cellular pathway for clearing and recycling damaged proteins and cellular components. This global Phase 2 study will test whether targeting this biology can translate into meaningful benefit for patients."

Swedish Alzheimer's Clinical Trial Expertise Comes to Taiwan

A major international component of the TML-6 program is the participation of seven clinical sites in Sweden, working with Anne Börjesson-Hanson, MD, PhD, of Karolinska Institute and Karolinska University Hospital.

Dr. Börjesson-Hanson is an experienced investigator in international Alzheimer's clinical trials, including studies of emerging disease-modifying therapies. Her clinical trial experience includes serving as Sweden's Clinical Trial Network establishment and participated in more than 40 global clinical trial as primary investigator, as well as leadership roles in other international Alzheimer's studies.

On October 4, Dr. Börjesson-Hanson will visit Taiwan for the Taiwan Dementia Society Annual Scientific Meeting. She will deliver a plenary lecture and meet with the nine Taiwanese principal investigators participating in the TML-6 study.

Nine Taiwan Medical Centers Join the TML-6 Global Study

Nine major Taiwan medical centers are participating in the same global Phase 2 study alongside the Swedish and U.S. sites, making Taiwan the largest group of participating clinical sites in the program.

"For Taiwan's biotechnology sector, this represents more than the advancement of one molecule," Dr. Su said. "It is an opportunity for a therapeutic program developed in Taiwan to contribute to the global effort to understand and treat Alzheimer's disease through a new biological approach."

The randomized, double-blind, placebo-controlled study will enroll approximately 210 participants with early Alzheimer's disease. Participants will receive TML-6 100 mg, TML-6 200 mg, or placebo once daily for 52 weeks. The primary endpoint is change from baseline in the Clinical Dementia Rating Sum of Boxes, a measure of cognition and daily function, and blood biomarkers p-Tau 217, Aβ, GFAP, and NfL as secondary endpoints.

The study also brings together international expertise in Alzheimer's biomarkers, imaging, and clinical development. Henrik Zetterberg, MD, PhD, will support blood biomarker analyses, while Barbara B. Bendlin, PhD, will contribute expertise in amyloid PET and MRI analyses. Gary W. Small, MD, serves as a global medical consultant, and Jacobo Mintzer, MD, advises on global clinical site execution.

Global Phase 2 Marks a Key Value Inflection Point for Business Development and Licensing

With TML-6 advancing into global Phase 2 development, Merry Life Biomedical is moving beyond early-stage safety evaluation toward the generation of clinical efficacy, biomarker, and imaging data. The company views the global Phase 2 study as a key value inflection point and, based on study progress and emerging data, will plan for Phase 3 development and broader global development strategies. Merry Life Biomedical is also actively exploring strategic investment, international venture capital, capital-market financing, and partnerships with global pharmaceutical companies to accelerate subsequent development. In parallel, the company will continue discussions with international pharmaceutical companies and strategic partners and, subject to Phase 2 results and regulatory strategy, evaluate licensing, co-development, and other partnership models to advance TML-6 through late-stage clinical development and toward global commercialization.

Forward-Looking Statements

This press release contains forward-looking statements regarding TML-6 and its clinical development that are subject to risks and uncertainties inherent in drug development. Statements regarding TML-6's mechanism and potential effects reflect hypotheses under clinical investigation and do not establish safety or efficacy.

SOURCE Merry Life Biomedical

Share this article

Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026

HONG KONG, Sept. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that nearly 30 clinical studies of its globally first-in-class bispecific antibodies will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place October 23–27 in Madrid, Spain. The presentations include one Late-Breaking Abstract (LBA) selected for the Presidential Symposium and two oral presentations.

Ivonescimab, the world's first approved PD-1/VEGF bispecific antibody, will be featured in 12 presentations at ESMO 2026. Notably, positive overall survival results from the Phase III HARMONi-GI1 trial evaluating ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer have been selected as a Late-Breaking Abstract for the Presidential Symposium and will be delivered as a late-breaking oral presentation. In addition, two rapid oral presentations will present breakthrough data on ivonescimab-based regimens as first-line treatment for advanced renal cell carcinoma and recurrent/metastatic thymic carcinoma. The presentations will also highlight ivonescimab's expanding development across multiple tumor types, including continued progress in lung cancer (including brain metastases), gastrointestinal cancers (esophageal and gastric cancer), and rare or difficult-to-treat malignancies such as pancreatic cancer, glioblastoma, endometrial cancer, thymic carcinoma, and head and neck squamous cell carcinoma.

Cadonilimab, the world's first PD-1/CTLA-4 bispecific antibody, will be featured in 15 presentations covering more than ten tumor types, including gastric cancer, renal cell carcinoma, lung cancer, esophageal squamous cell carcinoma, colorectal cancer, nasopharyngeal carcinoma, ovarian cancer, soft tissue sarcoma, pleural mesothelioma, and rectal cancer. These studies span neoadjuvant settings as well as first- and second-line treatment of advanced disease, underscoring the broad anti-tumor potential of this dual checkpoint inhibitor.

The extensive data to be presented at ESMO 2026 reflect Akeso's ongoing commitment to advancing next-generation immuno-oncology therapies for major global diseases and our continued efforts to build a differentiated global oncology portfolio. Full results will be released during the Congress. Please stay tuned for updates.

Key Presentations Highlights:

LBA8 - Ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: a randomized, controlled, double- blinded, Phase 3 trial (HARMONi-GI1)

- Speakers: Jian Zhou (Shanghai, China)

- Session Name: Presidential Symposium II

- Room: Alicante Auditorium - Hall 6

- Date: Sunday, 25 October 2026

- Time: 16:30 - 18:15 (Madrid)

Efficacy and Safety of AK112 (Ivonescimab), a PD-1/VEGF Bispecific Antibody, as First-Line Treatment for Patients with IMDC Favorable-Risk Advanced Renal Cell Carcinoma (aRCC): Results from a Phase Ib/II Study

- Session: Rapid Oral 2: Genitourinary tumours, renal and urothelial

- Abstract: 3592RO

- Presentation time: Sunday, 25 October 2026, 14:45–16:15 (Madrid)

- Presenter: Professor Xieqiao Yan, Peking University Cancer Hospital

Ivonescimab plus chemotherapy as first-line treatment in recurrent/metastatic thymic carcinoma: interim results from the iTHYM study

- Session: Rapid Oral: Non-metastatic NSCLC and other thoracic malignancies

- Abstract: 4156RO

- Presentation time: Monday, 26 October 2026, 10:15–11:45 (Madrid)

- Presenter: Professor Xue Hou, Sun Yat-sen University Cancer Center

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the Company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multi-specific antibodies and bispecific ADCs. Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.

Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

SOURCE Akeso, Inc.

Share this article

- Kakao Pay and Kakao Bank sign an MoU with global infrastructure leader Fireblocks to lay the groundwork for a digital asset ecosystem in Korea

- The companies will jointly explore Korean market opportunities in digital assets, including stablecoins

- The initiative aims to assess solutions suited to local regulatory, security, and service requirements

SEOUL, South Korea, Sept. 21, 2026 /PRNewswire/ -- Kakao Pay and Kakao Bank have signed a memorandum of understanding with Fireblocks to explore secure digital asset infrastructure in Korea.

The agreement is intended to help establish secure onchain infrastructure for Korea's emerging digital asset market and strengthen its early ecosystem. This initiative leverages Kakao's nationwide reach, expertise across fintech and banking, and core blockchain technology. The companies expect their collaboration with Fireblocks—which has deployed digital asset infrastructure for over 2,500 global institutions including more than 100 banks—to accelerate that effort.

Under the agreement, the three companies will jointly explore business opportunities based on Korea's market conditions and infrastructure demand. With a focus on stablecoins, they will explore digital asset distribution frameworks suited to Korea's regulatory, security, and service requirements. They also plan to conduct proof-of-concept (PoC) tests to assess the applicability of these frameworks, as part of a shared effort to build the digital asset ecosystem.

"For banks and payment platforms in Korea, leveraging reliable digital asset infrastructure that is engineered to meet institutional requirements from day one is critically important," said Michael Shaulov, CEO and Co-Founder of Fireblocks. "This is the prerequisite for widespread adoption, and Kakao Pay and Kakao Bank are setting the groundwork now."

"We are pleased to collaborate with Fireblocks, the global leader in digital asset infrastructure," said Yun Ho-young, CEO of Kakao Bank and Co-Head of Kakao Group's Stablecoin Task Force. "By combining our technology and expertise, we will develop secure and accessible digital asset services that expand our customers' financial opportunities."

"The success of Korea's emerging digital asset market depends on the reliable flow of digital asset distribution," said Shin Won-keun, CEO of Kakao Pay and Co-Head of Kakao Group's Stablecoin Task Force. "Our strategic alliance with Fireblocks, a leading global infrastructure provider, lays an important foundation for that."

About Fireblocks

Fireblocks is the world's most trusted digital asset infrastructure company, empowering global institutions to build, manage and grow their business on the blockchain. With the industry's most scalable and secure platform, we streamline stablecoin payments, settlement, custody, tokenization, trading, accounting operations, and compliance reporting - enabling everything from institutional finance to consumer-facing digital experiences across the largest ecosystem of banks, payment providers, stablecoin issuers, exchanges and custodians. Thousands of organizations - including Worldpay, BNY, Galaxy, and Revolut - trust Fireblocks to secure $16 trillion in digital asset transactions across 200+ blockchains. Learn more at fireblocks.com

SOURCE Fireblocks

Share this article

Respected transportation executive brings decades of experience leading major transit, aviation and infrastructure agencies and helping advance innovation across the transportation industry

DENVER, Sept. 21, 2026 /PRNewswire/ -- Phillip A. Washington has joined HNTB as president of strategy and client service, markets and services, and senior vice president, further deepening the firm's leadership in the transportation industry.

"Phil is one of the most respected and influential leaders in transportation," said Mike Inabinet, PE, president of markets and services at HNTB. "His successful track record of leading organizations, shaping policies and building lasting relationships across our industry will help advance client programs while bringing valuable perspective on the ideas, innovations and investments shaping the future of transportation."

In his new position, Washington will collaborate with professionals across HNTB's transportation markets, services and offices to identify emerging opportunities, strengthen strategic client engagement and help advance solutions that address the evolving needs of transportation agencies and infrastructure owners as they navigate an increasingly connected and rapidly changing transportation landscape.

Washington most recently served as chief executive officer of Denver International Airport, where he led one of the world's busiest airports and oversaw a multibillion-dollar capital improvement program focused on capacity, customer experience, safety and long-term growth. Prior to Denver, he served as chief executive officer of the Los Angeles County Metropolitan Transportation Authority, where he led an 11,000-person organization responsible for the largest modern public works program in North America and helped advance major transit, highway and mobility investments throughout Los Angeles County. Earlier in his career, he served as chief executive officer of Denver's Regional Transportation District, leading delivery of the FasTracks expansion program and the redevelopment of Denver Union Station.

"I've spent my career in public service and transportation, focused on bringing people together to solve complex challenges and create meaningful outcomes for communities," Washington said. "As I considered the next chapter of my career, what drew me to HNTB was its culture, its people and its longstanding leadership in helping clients deliver some of the industry's most significant programs. HNTB is helping lead on the most important projects and conversations shaping the future of the industry, and I look forward to working alongside our exceptionally talented professionals to build on that legacy while creating new opportunities for our clients and communities."

Throughout his career, Washington has been recognized for both industry leadership and public service. He was inducted into the American Public Transportation Association (APTA) Hall of Fame in 2023 after previously being named Outstanding Public Transportation CEO of the Year in North America by APTA. He also served as chair of APTA from 2014-2015. In 2018, he received the Honorable Ray LaHood Award from the Women's Transportation Seminar for his contributions to helping advance and advocate for women in the transportation industry. In 2017, Washington was awarded the prestigious Norman Mineta Award from the Mineta Transportation Institute in recognition of his leadership in the transportation industry.

A 24-year veteran of the U.S. Army, Washington retired with the rank of Command Sergeant Major, the highest noncommissioned officer rank achievable by an enlisted soldier. He is a disabled veteran and holds a bachelor's degree in business from Columbia College and a master's degree in management from Webster University. He also is a graduate of the Harvard University Kennedy School for Senior Executives in State and Local Government.

About HNTB

For more than a century, HNTB Corporation has been at the forefront of designing and advancing transportation infrastructure that enhances mobility and improves local communities. With client relationships spanning decades, we understand infrastructure life cycles and have perspective and experience to solve the most complex technical, financial and operational challenges with vision and imagination. As employee owners committed to excellence, we prioritize client success while delivering a full spectrum of infrastructure-related services. Discover HNTB's Spark at www.hntb.com, or follow us on LinkedIn, X, Facebook or Instagram.

SOURCE HNTB Corporation

Share this article